Assenagon Asset Management S.A. Grows Position in Medpace Holdings, Inc. $MEDP

Assenagon Asset Management S.A. grew its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 1,499.6% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 116,323 shares of the company’s stock after acquiring an additional 109,051 shares during the quarter. Assenagon Asset Management S.A.’s holdings in Medpace were worth $55,857,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also modified their holdings of the company. Optiver Holding B.V. purchased a new position in shares of Medpace in the third quarter valued at $27,000. Geneos Wealth Management Inc. increased its position in Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares during the last quarter. Steigerwald Gordon & Koch Inc. purchased a new stake in Medpace during the fourth quarter valued at $30,000. Elyxium Wealth LLC purchased a new stake in Medpace during the fourth quarter valued at $30,000. Finally, Quarry LP purchased a new stake in Medpace during the third quarter valued at $35,000. 77.98% of the stock is owned by hedge funds and other institutional investors.

Medpace Stock Up 1.4%

MEDP stock opened at $519.96 on Friday. Medpace Holdings, Inc. has a twelve month low of $305.69 and a twelve month high of $628.92. The stock has a market capitalization of $14.85 billion, a price-to-earnings ratio of 32.68, a price-to-earnings-growth ratio of 2.60 and a beta of 1.18. The firm’s fifty day simple moving average is $451.02 and its two-hundred day simple moving average is $496.81.

Medpace (NASDAQ:MEDP) last released its earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.74 by $0.54. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The firm had revenue of $706.60 million during the quarter, compared to analyst estimates of $697.82 million. During the same quarter last year, the business earned $3.67 EPS. The business’s revenue was up 26.5% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, equities research analysts expect that Medpace Holdings, Inc. will post 17.04 EPS for the current year.

Insiders Place Their Bets

In other Medpace news, General Counsel Stephen P. Ewald sold 16,349 shares of the firm’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $450.00, for a total value of $7,357,050.00. Following the completion of the sale, the general counsel owned 20,343 shares of the company’s stock, valued at $9,154,350. This trade represents a 44.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 20.50% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

MEDP has been the subject of a number of recent research reports. Wall Street Zen cut shares of Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Royal Bank Of Canada reduced their target price on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating on the stock in a report on Friday, April 24th. Weiss Ratings cut shares of Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, April 6th. Robert W. Baird lowered their price target on shares of Medpace from $565.00 to $477.00 and set an “outperform” rating for the company in a report on Friday, April 24th. Finally, Barclays dropped their price target on Medpace from $500.00 to $450.00 and set an “equal weight” rating for the company in a research report on Friday, April 24th. Four investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $467.08.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.